AUA 2018

AUA 2018: Biomarker Debate: Adopt, Expand, Trust (PRO)

San Francisco, CA (UroToday.com) Matt Cooperberg, MD provided the pro position for the use of biomarkers in prostate cancer at the much-anticipated biomarker debate at the International Prostate Forum at the 2018 AUA meeting. Cooperberg started his talk by highlighting the current biomarker landscape in 2018:

AUA 2018: Biomarker Debate: Adopt, Expand, Trust (CON)

San Francisco, CA (UroToday.com) Ben Davies, MD from the University of Pittsburgh provided the rebuttal to Matt Cooperberg’s argument for prostate cancer biomarkers. Davies started with a case of a 51-year-old healthy man with a PSA of 6 and one core of Gleason 3+4 prostate cancer. A Decipher test score of <0.45 would place this gentleman in the low genomic classifier group, and coupled with being NCCN low-favorable intermediate risk, this would give this patient a 6-tier clinical-genomic risk group score of 1 (low risk). More to come from this case…

AUA 2018: Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018

San Francisco, CA (UroToday.com) David F. Jarrard, MD provided an update on the CRPC AUA guideline amendment at 113th Annual Scientific Meeting of the American Urological Association (AUA). Dr. Jarrard highlights, the six index patients associated with the CRPC guidelines assists in clinical decision making, representing the most common clinical scenarios that are encountered in clinical practice. Guideline statements are developed to provide a rational basis for treatment based on currently available published data. The purpose of this guideline amendment is essentially to update current management of index patient 1: asymptomatic non-metastatic CRPC (nmCRPC).

AUA 2018: Noctiva: Addressing a Nighttime Condition with Daytime Consequences

San Francisco, CA (UroToday.com) The purpose of this presentation was to introduce Noctiva as an only FDA-approved treatment option available for patients with diagnosed polyuria, educate healthcare specialists on use of medication, and review concurrent case studies of individuals who were prescribed this medication.

AUA 2018: A Randomized Trial of a Group-Based Therapeutic Yoga Program for Ambulatory Women with Urinary Incontinence

San Francisco, CA USA (UroToday.com) This podium session began with a study that evaluated a new approach to the treatment of urinary incontinence (UI). Alternatives to current treatments for overactive bladder are needed, especially for older patients who are more susceptible to the side effects of anticholinergic medications. The practice of yoga has become very popular in the last decade and is thought to have many benefits including increased strength, balance, and flexibility, as well as to decrease stress.

AUA 2018: Prevalence of Nocturia in US Women: Results from NHANES

San Francisco, CA (UroToday.com) The primary purpose of this study was to assess possible causes and overall prevalence of severe nocturia (≥ 2 per night) in the US women. Researchers state that current prevalence data is underestimated due to following reasons. Data show that average individual starts seeking medical help for nocturia in 2 years after first disease manifestation.

AUA 2018: Improved Sleep Quality Following Adenotonsillectomy is Associated with Enuresis Resolution in Children with Sleep Disordered Breathing.

San Francisco, CA (UroToday.com) In this prospective pilot study, researchers analyzed how adenotonsillectomy (TA) in children would affect their overall sleep quality, nocturnal urinary volume, and secretion of antidiuretic hormone (ADH) and brain natriuretic peptide (BNP).